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Purpose: The aim of this study was to evaluate the relationship between body composition, 
metabolic profile, adipokines, and carotid intima-media thickness (cIMT) in young survivors 
of childhood acute lymphocytic leukemia (ALL).
Patients and methods: This cross-sectional study compared 55 ALL survivors, of chrono-
logical age between 15 years and 24 years, assigned into two groups according to the exposure 
to cranial radiation therapy (CRT; 25 irradiated and 30 nonirradiated) with 24 leukemia-free 
controls, and assessed body fat mass (dual-energy X-ray absorptiometry), computed tomography 
scan-derived abdominal adipose tissue, lipid profile, blood pressure (BP), adipokines, and cIMT 
by a multiple regression analysis.
Results: Treatment with CRT had an effect on all of the variables derived from the computed 
tomography scan: visceral adipose tissue (VAT) and subcutaneous adipose  tissue (SAT) 
(P,0.050). In a multiple linear regression model, cIMT positively correlated with exposure 
to CRT (P=0.029), diastolic BP (P=0.016), and leptin-to-adiponectin ratio (P=0.048), while 
negatively related to SAT (P=0.007).
Conclusion: In young survivors of childhood ALL, CRT modified the distribution of fat 
and played a critical role in determining cIMT. Leptin-to-adiponectin ratio, a biomarker of 
abdominal obesity and metabolic syndrome, and diastolic BP also influenced cIMT, a marker 
of subclinical atherosclerosis. Nonetheless, adiposity-associated vascular disease might be 
attenuated by SAT. Changes in body fat must be evaluated in this group of patients in the 
early course of survivorship in order to avoid premature cardiovascular disease associated 
with atherosclerosis. Yet, further research as regards the possible protective effect of SAT on 
vascular disease is warranted.
Keywords: precursor cell lymphoblastic leukemia–lymphoma/radiotherapy, abdominal fat, 
metabolic syndrome X, adipokines, endothelium, atherosclerosis
Introduction
Acute lymphocytic leukemia (ALL) is the most prevalent type of cancer in child-
hood.1 As an increasing number of cancer survivors reaches adulthood, there may be 
consequences of the treatment, especially adiposity and components of the metabolic 
syndrome (MS), which predispose to cardiovascular disease (CVD) and enhance 
mortality.2–10 According to the recommendations of the American Association of Car-
diology in collaboration with the Council for Cardiovascular Disease in the Young,3 
based on the pediatric conditions and their risk of CVD, patients treated for childhood 
cancer should be classified as tier III, which means the presence of clinical criteria for 
MS and increased epidemiological risk of premature CVD.2–10
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The pathophysiology of atherosclerosis involves many 
factors, such as endothelial dysfunction and chronic 
inflammation of the arteries.11,12 Insulin resistance 
(IR), hyperinsulinemia, and increased fatty free acids 
are  considered the initial mechanisms of endothelial 
 dysfunction, which  progress to atherosclerosis,12,13 being 
worsened by other aspects, such as dyslipidemia, smok-
ing, diabetes mellitus, and hypertension.11,12 Subclinical 
atherosclerosis may be detected by the increment of carotid 
intima-media thickness (cIMT), a simple and noninvasive 
method, which  encompasses an intermediate marker of 
CVD.14–18
Adipokines, comprising adiponectin, leptin, resistin, 
cytokines, and monocyte chemoattractant protein-1 (MCP-
1), are also associated with endothelial dysfunction and 
 atherogenesis. Adiponectin, as well as leptin-to-adiponectin 
ratio, is related to cIMT, and is considered a reliable  indicator 
for atherosclerosis.19,20 In addition, the upregulation of 
endothelial cell MCP-1 production by low-density  lipoprotein 
(LDL) oxidation is considered a major initiating event in 
atherogenesis.21
In cancer survivors, the risk factors for vascular structural 
and functional modifications include those related to the 
patient, disease, or treatment, especially chemotherapy and 
cranial radiation therapy (CRT) and/or cervical radiation 
therapy, but also hormonal deficiencies and the association 
with the components of the MS.4,14–18
Nonetheless, there are few studies as regards the relation-
ship between ALL, the exposure to CRT, the components 
of the MS, and the endothelium structure,2,8 and there is no 
study evaluating the adipokines in this context. Thus, the aim 
of this study was to evaluate the effect of body composition, 
metabolic profile, and adipokines on cIMT in young survivors 
of childhood ALL.
Materials and methods
study population
This was a comparative cross-sectional study of a randomly 
selected sampling of ALL survivors of both sexes from the 
Pediatric Oncology Institute (Federal University of Sao 
Paulo, Brazil), admitted from May 1991 to June 2003, and 
a leukemia-free control group. The study was approved by 
the Ethics Research Committee of Federal University of 
Sao Paulo (Number 1197/07). To participate in this study, 
patients or parents, when appropriate, signed an informed 
consent form.
ALL subjects completed the Brazilian Cooperative 
Group for Treatment of Childhood Acute Lymphocytic 
Leukemia (GBTLI) international protocol. Details 
comprising drugs and CRT can be read elsewhere.22,23 
CRT was applied prophylactically to those at high risk of 
relapse, defined according to the recommendations of the 
GBTLI, and/or therapeutically to those with central nervous 
system involvement, defined as blast cells greater than 5% 
in cerebrospinal fluid.22,23
The inclusion criteria comprised the following: chrono-
logical age between 15 years and 24 years; the complete 
clinical remission of ALL (complete absence of the disease 
in bone marrow and blood); no ALL therapy for at least 
2 years; complete pubertal development (menarche in girls 
and  Tanner stage IV or above in boys);24,25 growth of less than 
1 cm/year; bone age with full epiphyseal plate fusion; normal 
renal, thyroid, gonadal, and adrenal profiles (spontaneous 
or under hormonal replacement therapy); and insulin-like 
growth factor-1 (IGF-1) within the normal range. The 
following were excluded from the study: patients who used 
anorexigens, insulin-sensitivity medications, or other drugs 
that interfere with adiposity (eg, metformin, sibutramine, 
and fluoxetine); those who had experienced exogenous 
growth hormone (GH) administration within 2 years prior 
to study enrollment or a bone marrow transplantation; and 
those who were pregnant, were postpartum, or had Down’s 
syndrome.
Survivors were stratified into two groups according 
to the exposure to CRT (irradiated and nonirradiated). 
Characteristics of host/disease and therapy were assessed 
from clinical examinations and/or medical records, encom-
passing sex, age at ALL diagnosis, age at assessment, age 
at the time of receiving and dose of CRT (if employed), 
time post-therapy, medications, or eventful past medical 
history.
The control group was selected among peers and/or 
relatives of the ALL patients, and was composed of healthy, 
leukemia-free subjects of similar age and body mass index 
(BMI), who did not use any medication.
Variables
All the variables were determined for both ALL patients 
(irradiated or not) and the control group.
adiposity indexes
Adiposity indexes comprised body composition and fat 
distribution variables. Body composition encompassed 
BMI and fat mass index (FMI). BMI was calculated as the 
weight in kilograms divided by height in meters squared, 
and converted to Z scores based on the National Center 
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for Health Statistics 2000 Centers for Disease Control and 
Prevention growth charts.26 The FMI was calculated as the 
fat mass (in kilograms) divided by height in meters squared 
(kg/m2), body fat mass being assessed by dual-energy X-ray 
absorptiometry, Hologic Discovery 4500 (QDR-4500A; 
Hologic Inc., Bedford, MA, USA).
Fat distribution indexes comprised computed tomography 
(CT) scan-derived abdominal adipose tissue, encompassing 
visceral adipose tissue (VAT) and subcutaneous adipose 
tissue (SAT), both measured according to the method 
described elsewhere.6,9
Blood pressure, metabolic profile, and growth factor
Systolic blood pressure (BP) and diastolic BP (in mmHg) 
were both measured with the patient in the sitting position 
after 5 minutes of rest in a tranquil environment, by ausculta-
tion, at an average of three outlets in the right arm (Tycos® 
Welch Allyn, NY, USA).
Metabolic profile included LDL cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C), and triglyc-
erides (enzymatic colorimetric method, in mmol/L). Glucose 
values (method: automated) and insulin (method: ACTIVE® 
Insulin ELISA DSL-10-1600; Diagnostics Systems Labo-
ratories, Inc., Webster, TX, USA) were used to calculate 
the homeostasis model assessment – insulin resistance 
(HOMA1-IR).27
IGF-1 (in nmol/L) was analyzed by a sandwich assay, 
one-step chemiluminescence using coated magnetic 
microparticles (LIAISON® IGF-1 OS-313, 231; Gruppe Bio-
medica, Inc., Vienna, Austria), whose intra-assay coefficient 
of variability (CV) and inter-assay CV were, respectively, 
3.7% and 4.6%, with minimum detection limit of 3.0 ng/mL 
and 100% of specificity.
adipokines
1. Leptin-to-adiponectin ratio (ng/µg): leptin (in ng/mL) 
being analyzed by “Dual Range” enzyme-linked immuno-
sorbent assay (ELISA) (Linco Research, Inc., St Charles, 
MO, USA; catalog number EZHL-80SK) with intra-
assay CV of 3.6%, inter-assay CV of 4.0%, minimum 
detection limit of 0.5 ng/mL, and specificity of 100%, and 
adiponectin (in µg/mL) being evaluated by ELISA (R&D 
Systems, Inc., Minneapolis, MN, USA; catalog number 
DY1065) with intra-assay CV of 6.2%, inter-assay CV 
of 7.2%, minimum detection limit of 0.1 ng/mL, and 
specificity of 100%.
2. MCP-1 (in pg/mL): ELISA (R&D Systems, Inc.; cata-
log number DY279) with intra-assay CV below 10%, 
inter-assay CV below 15%, minimum detection limit of 
10 pg/mL, and specificity of 100%.
carotid intima-media thickness
cIMT was measured in the supine position, 1.0 cm below 
the carotid bulb of right and left common carotid arteries 
(Sonos 5500, Hewlett Packard®), coupled to a high-resolution 
linear transducer with frequency up to 11 MHz, and image 
acquisition was performed in the longitudinal plane in two-
dimensional mode, with simultaneous cardiac monitoring, 
by one of two experienced observers, whose intraobserver 
variation was 0.05±0.02 mm and interobserver variation 
was 0.07±0.04 mm. The measurement was performed in 
the anterior or posterior wall of the artery, in the distance 
between two lines represented by the echogenic interfaces 
lumen-intima and media-adventitia of carotid wall. For each 
side (right and left), the result was calculated by the average 
of the measurements of three consecutive cardiac cycles, 
taking into consideration the R wave peak.28 Subsequently, 
the mean measurement of both sides was used for further 
analyses: (right cIMT + left cIMT)/2.
statistical analysis
Statistical analysis was initially made in a descriptive way 
through some summary measures such as mean, median, 
minimum and maximum values, standard deviation (SD), and 
absolute and relative frequencies (percentage). The inferential 
analyses were the following:
•	 As regards exposure to CRT/group (nonirradiated ALL 
patients vs irradiated ALL patients vs control subjects): 
Kruskal–Wallis test, with Bonferroni–Dunn post hoc test 
for pairwise comparisons if statistically significant, in the 
comparison of age at assessment (years), BMI (Z score), 
VAT (cm3), SAT (cm3), HOMA1-IR, triglycerides 
(mmol/L), systolic and diastolic BP (mmHg), IGF-1 
(nmol/L), leptin-to-adiponectin ratio (ng/µg), MCP-1 
(pg/mL), and cIMT (mm); one-way analysis of variance, 
with Duncan post hoc test for pairwise comparisons if 
statistically significant, in the comparison of FMI (kg/m2), 
LDL-C (mmol/L), and HDL-C (mmol/L); and Student’s 
t-test for independent samples in the comparison of time 
post-therapy (years) between ALL subjects.
•	 As regards sex of ALL patients: Mann–Whitney test in the 
comparison of age at assessment (years), BMI (Z score), 
FMI (kg/m2), VAT (cm3), SAT (cm3), HOMA1-IR, 
triglycerides (mmol/L), diastolic BP (mmHg), IGF-1 
(nmol/L), leptin-to-adiponectin ratio (ng/µg), MCP-1 
(pg/mL), and cIMT (mm); and Student’s t-test for 
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independent samples in the comparison of time post-
therapy (years), LDL-C (mmol/L), HDL-C (mmol/L), 
and systolic BP (mmHg).
•	 As regards sex of the control group: Mann–Whitney test 
in the comparison of FMI (kg/m2), VAT (cm3), SAT 
(cm3), HOMA1-IR, triglycerides (mmol/L), systolic BP 
(mmHg), and cIMT (mm); and Student’s t-test for inde-
pendent samples in the comparison of age at assessment 
(years), BMI (Z score), LDL-C (mmol/L), HDL-C 
(mmol/L), diastolic BP (mmHg), IGF-1 (nmol/L), leptin-
to-adiponectin ratio (ng/µg), and MCP-1 (pg/mL).
•	 Multiple linear regression analysis to study the relation-
ship of cIMT (mm) according to the exposure to CRT, 
VAT (cm3), SAT (cm3), LDL-C (mmol/L), HDL-C 
(mmol/L), triglycerides (mmol/L), systolic and diastolic 
BP (mmHg), leptin-to-adiponectin ratio (ng/µg), and 
MCP-1 (pg/mL), among ALL subjects.
•	 To further explore the relation between VAT and SAT 
among ALL patients, the VAT-to-SAT ratio was deter-
mined, and the relationship between this ratio and cIMT 
was evaluated by Pearson’s correlation.
Statistical analyses were performed with the Statistical 
Package for the Social Sciences (SPSS) version 19.0 for 
Windows and R version 2.15.2. In all tests, P,0.050 was 
considered as statistically significant.
Results
subject’s characteristics
The selected sample in this study consisted of 79 subjects, 55 
being (69.6%) ALL patients, and 24 (30.4%), controls.
The age at assessment of the ALL patients was (given as 
mean with SD in parentheses) 18.6 (2.5) years, ranging from 
15.0 years to 22.9 years, age at ALL diagnosis was 7.4 (3.9) 
years, and time post-therapy was 8.5 (3.5) years. Controls 
were 19.8 (3.1) years at study assessment, ranging from 
14.3 years to 24.9 years. While compared to nonirradiated 
ALL subjects, controls were older (post hoc test, P=0.049) 
(Table 1).
The ALL subjects were composed of 31 (56.4%) women 
and 24 (43.6%) men. The control group comprised 14 
(58.3%) women and 10 (41.7%) men.
ALL subjects completed the GBTLI international 
protocol, and 25 (45.4%) ALL survivors received CRT with a 
dose of either 18 Gy (76%) or 24 Gy (24%) at a mean age of 
8.0 (4.0) years. Three subjects also received alternative proto-
cols to the GBTLI, which were employed due to medullar or 
testicular relapses but without complementary CRT. Among 
the irradiated survivors, one subject also received spinal 
irradiation, and two patients received testicular radiation 
therapy (24 Gy).
Body composition, fat distribution, 
and ciMT
FMI was increased in female sex in both groups of patients, 
ALL subjects and controls (P,0.050), and showed a trend 
toward an increase in ALL patients subjected to CRT 
(P=0.078). (Table 1 presents the comparison with regard 
to CRT exposure/group, and Table 2 presents further data 
as regards sex between ALL subjects.) Data regarding sex 
among controls are not shown.
VAT (post hoc test, P=0.018) and SAT (post hoc test, 
P=0.050) were increased among irradiated compared to non-
irradiated ALL subjects, with no difference while compared 
to the controls. Concerning sex, no differences in VAT 
or SAT were detected in either ALL subjects or controls 
(Tables 1 and 2).
cIMT showed no difference as regards CRT exposure/
group or sex, in both ALL subjects and controls (Tables 1 
and 2).
Metabolic profile, adipokines, and BP
While analyzing data regarding the three groups (Table 1), 
LDL-C was increased in both irradiated ALL patients and 
controls, when compared to nonirradiated ALL patients (post 
hoc test, P,0.050), and MCP-1 was increased in controls 
(P=0.046), but no significant difference was determined in 
a post hoc test analysis.
When comparing sexes among ALL patients (Table 2), 
HDL-C was decreased (P=0.006), while both systolic BP 
(P=0.028) and leptin-to-adiponectin ratio (P=0.011) were 
increased in ALL males.
There were no other statistically significant differences 
with respect to other characteristics measured and shown 
in Table 1 or 2, or regarding sex among the control group 
(data not shown).
Multiple linear regressions
This analysis was performed among ALL patients and 
showed that cIMT was positively related to the exposure 
to CRT (P=0.029), diastolic BP (P=0.016), and leptin-to-
adiponectin ratio (P=0.048), while negatively related to 
SAT (P=0.007).
In the presence of exposure to CRT, SAT, diastolic BP 
and leptin-to-adiponectin ratio, VAT (P=0.437), LDL-C 
(P=0.252), HDL-C (P=0.411), triglycerides (P=0.390), sys-
tolic BP (P=0.977), and MCP-1 (P=0.741) did not influence 
cIMT. Table 3 presents model adjustment.
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VaT-to-saT ratio
cIMT and VAT-to-SAT ratio were positively correlated 
among ALL patients, as shown in Figure 1 (r=0.355, 
P=0.008).
Discussion
This study investigated the effect of fat distribution, lipid 
profile, BP, and adipokines on cIMT in young survivors of 
childhood ALL, and showed that even though CRT led to 
abdominal accumulation of fat and positively determined 
cIMT, a noninvasive assessment of subclinical atherosclerosis, 
SAT might represent a protective factor against adiposity-
associated vascular disease.
The increase in cIMT in some groups of cancer survivors, 
particularly patients with brain tumors and Hodgkin’s 
lymphoma, has been explained by a local effect of CRT and/
or neck irradiation, which is dose-dependent, and influenced 
by other factors, such as chronological age, time since 
CRT, and association with components of the MS and GH 
insufficiency.4,10 An increase in cIMT has been observed in 
the group of patients who were treated with high doses of 
CRT (54 Gy) and/or cervical irradiation.4,14,16–18,29
Table 2 Summary measures of general characteristics, body composition and fat distribution, metabolic profile, blood pressure, 
and adipokine levels of all patients, according to sex
Sex
Female Male
n Mean Median Min Max SD n Mean Median Min Max SD P value
age at assessment  
(years)
31 18.4 18.1 15.0 22.9 2.7 24 18.9 18.6 15.0 22.8 2.3 0.401m
Time post-therapy  
(years)
31 8.5 8.0 4.0 16.4 3.5 24 8.5 8.4 2.5 14.3 3.5 0.968t
BMi (Z score) 31 0.15 0.26 -2.55 1.96 1.04 24 0.00 0.30 -2.88 2.14 1.36 0.665m
FMi (kg/m2) 31 7.8 7.3 3.2 15.5 2.8 24 5.2 4.3 1.8 11.8 3.1 0.001m
Visceral adipose  
tissue (cm3)
31 99.3 81.3 24.0 250.9 59.1 24 124.7 100.6 21.9 265.3 69.2 0.149m
subcutaneous  
adipose tissue (cm3)
31 386.1 359.5 96.9 1,077.4 205.2 24 320.9 270.1 36.2 934.2 265.3 0.096m
HOMa1-iR 31 2.00 1.63 0.80 4.75 1.00 24 2.03 1.62 0.71 4.49 1.13 0.859m
lDl-c (mmol/l) 31 2.3 2.3 1.1 3.5 0.7 24 2.2 2.0 0.8 4.1 0.8 0.545t
HDl-c (mmol/l) 31 1.3 1.3 0.4 1.9 0.3 24 1.1 1.1 0.6 1.4 0.2 0.006t
Triglycerides  
(mmol/l)
31 1.0 0.9 0.3 2.4 0.6 24 1.0 0.8 0.5 1.9 0.5 0.939m
systolic blood  
pressure (mmHg)
31 107.3 106.7 90.0 122.0 8.9 24 114.0 113.3 88.3 144.3 13.0 0.028t
Diastolic blood  
pressure (mmHg)
31 68.4 66.7 56.7 80.0 5.8 24 73.1 70.0 56.7 100.0 10.9 0.151m
igF-1 (nmol/l) 31 39.9 34.7 20.6 70.5 15.4 24 41.8 36.2 20.2 81.2 15.7 0.530m
leptin-to-adiponectin 
ratio (ng/µg)
31 2.92 2.35 1.16 9.11 1.90 24 3.85 3.27 1.58 8.02 1.88 0.011m
McP-1 (pg/ml) 31 101.5 92.1 45.8 198.3 44.9 24 104.9 88.5 30.7 278.9 67.8 0.641m
ciMT (mm) 31 0.61 0.63 0.50 0.78 0.06 24 0.64 0.62 0.53 0.90 0.09 0.463m
Notes: mMann-Whitney test; tstudent’s t-test for independent samples.
Abbreviations: all, acute lymphocytic leukemia; min, minimum value; max, maximum value; sD, standard deviation; BMi, body mass index; FMi, fat mass index; HOMa1-
iR, homeostasis model assessment – insulin resistance; lDl-c, low-density lipoprotein cholesterol; HDl-c, high-density lipoprotein cholesterol; igF-1, insulin-like growth 
factor-1; McP-1, monocyte chemoattractant protein-1; ciMT, carotid intima-media thickness.
Table 3 estimated parameters from multiple linear regression model, with the dependent variable being carotid intima-media thickness, 
among all patients
Coefficient Standard error (coefficient) t P value
(constant) 0.420640 0.077123 5.454 ,0.001
exposure to cRT 0.044374 0.019753 2.246 0.029
saT (cm3) -0.000128 0.000045 -2.830 0.007
Diastolic blood pressure (mmHg) 0.0028815 0.001131 2.488 0.016
leptin-to-adiponectin ratio (ng/mcg) 0.009745 0.004807 2.027 0.048
Abbreviations: all, acute lymphocytic leukemia; cRT, cranial radiation therapy; saT, subcutaneous adipose tissue.
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In the present study, there was no significant difference 
in cIMT, taking into account CRT treatment or sexes. This 
finding is in accordance with previous studies concerning 
ALL survivors who received either low doses of CRT or no 
radiation, either adult long-term survivors or those who had 
just received their treatment, survivors who did not show any 
increase in carotid vascular measures, while compared to 
normal controls.2,29 It should be noted, however, that contrary 
to brain tumor survivors, patients treated for ALL receive less 
radiation overall and not specifically to the neck region. One 
of these studies in ALL survivors demonstrated only vascular 
dysfunction (but not increase in cIMT), as a marker of sub-
clinical atherosclerosis, which was not evaluated in the pres-
ent sample of ALL survivors so far.29 Conversely, the present 
sample of ALL survivors showed an increase in cIMT, while 
compared to patients selected from the Brazilian Metabolic 
Syndrome Study, matched by sex, chronological age, and 
BMI.30 Although age and sex are nonmodifiable elements 
that should be taken into account for vascular evaluation,31 
to date, it is not possible to state that time off therapy, dose of 
CRT, sex, and chronological age have influenced the results 
in the present study, since patients were relatively young, 
evaluated with few time off therapy, and received low doses 
of CRT.4,14,16–18,29,31
CRT played a role in cIMT among this sample of young 
survivors of ALL, and might be considered a positive predictor 
of subclinical atherosclerosis, even though it is not possible to 
determine the critical dose of CRT associated with an increase 
in vascular structure so far. The exposure to CRT in ALL 
survivors caused a change in the distribution of fat, predomi-
nantly in the abdominal region, as previously documented in 
a study with this sample of ALL patients.6 Since the exact 
mechanism by which CRT modifies adipose tissue distribution 
is unknown, it is possible to declare that there was a relation-
ship between the exposure to CRT and cIMT in this sample 
of ALL survivors. Excessive abdominal fat accumulation has 
been considered a frequent adverse effect in the period of the 
rebound of adiposity, and many years after therapy withdrawal 
in ALL survivors, particularly those exposed to CRT. CRT 
may affect energy regulatory pathways and the hypothalamic 
metabolic circuits resulting in body fat alterations. A hypo-
thalamic insult, such as CRT or intrathecal methotrexate, may 
lead to modifications in satiety centers or increase parasym-
pathetic tone. Moreover, GH deficiency, which might occur 
in ALL patients subjected to CRT, may have an impact on 
body composition and metabolic profile.2–6,9,32
SAT was a negative predictor of cIMT in this sample 
of young survivors of ALL, which concurs with previous 
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Figure 1 scatterplot and trend line between carotid intima-media thickness and visceral-to-subcutaneous adipose tissue ratio, among all patients. 
Note: Pearson’s correlation; r=0.355, P=0.008.
Abbreviations: all, acute lymphocytic leukemia; VaT, visceral adipose tissue; saT, subcutaneous adipose tissue; ciMT, carotid intima-media thickness.
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statements that have evaluated the relationship between 
VAT and SAT.33,34 Furthermore, the VAT-to-SAT ratio 
also played a positive role in cIMT among ALL subjects. 
It appears that there is an interaction of SAT by modifying 
adverse effects of VAT, or the adverse effects of VAT might 
be lessened with increasing amounts of SAT. Nonetheless, 
SAT seems to display less insulin- and adrenergic-related 
lipolytic activity, to release fewer inflammatory adipokines 
and to have greater adiponectin expression, compared to 
VAT. The mechanisms that may underlie the potential 
beneficial effects of SAT in the presence of high amounts 
of VAT are not clear so far.33,34
Diastolic BP showed a positive effect on cIMT in this 
sample of patients treated for ALL, but there was no relation-
ship between cIMT and HOMA1-IR or lipid profile, which 
concurs with previous studies,20 even though factors associ-
ated with MS, such as HDL-C, LDL-C, and IR, potentially 
aggravate endothelial dysfunction and atherogenesis.12,35,36 In 
relation to hormonal deficiencies, especially GH deficiency, 
there were no statistical differences in IGF-1 levels while 
comparing groups, even though the group exposed to CRT 
showed lower levels, not clinically relevant and within the 
normal limits so far.
This study is the first to describe the relationship between 
cIMT, components of the MS, and adipokines in patients 
treated for ALL, either exposed or not to CRT. Leptin-to-
adiponectin ratio, which reflects abdominal fat accumulation 
and is a biomarker of the MS, was associated with cIMT 
in this sample of young survivors of ALL, which has been 
previously described.19,20 Even though oxidized LDL-C may 
increase adherence and penetration of macrophages in the 
endothelial cell, this is a local event, and might explain why 
MCP-1 levels were not related to cIMT in this study.21
This study included 55 survivors of ALL from a single 
institution, at a mean 8.5 years posttreatment, younger, 
at a shorter posttreatment interval compared to other 
studies, and none currently assessed within the period of 
the adiposity rebound, which features the 2 years after 
treatment withdrawal, in which there is an increment of 
the adiposity indexes.2,5,8,9,32,37 The sample size was small, 
and this may be considered a limitation of the study. It is 
noteworthy, however, that even though some of the char-
acteristics of the control group (age, FMI, lipid profile, 
and adipokines) resemble those of the irradiated ALL 
patients, VAT and SAT were probably increased by CRT 
exposure, considering that this sample of ALL patients 
received intense medical support, overprotection due to 
illness, and parental caregiving, therefore reinforcing the 
deleterious effect of CRT on abdominal accumulation of 
fat among ALL survivors. Patients not subjected to CRT 
were younger than leukemia-free controls; however, this 
difference regarding age was not clinically relevant. ALL 
patients subjected to CRT may have undergone preceding 
GBTLI protocols (GBTLI-85 and GBTLI-93),22,23 which 
indicated prophylactic CRT to all patients at risk of relapse. 
Concerning CRT and its detrimental effects, the latest 
GBTLI-99 protocol has reserved therapeutic CRT entirely 
to patients with central nervous system involvement so that 
patients treated for ALL are not exposed to prophylactic 
CRT so far.23 Another aspect to be emphasized is that this 
study did not evaluate the endothelium function but only 
structural alterations of carotid wall. Moreover, there are 
no data concerning cIMT and/or adipokines before or dur-
ing ALL therapy.
Conclusion
In young survivors of childhood ALL, CRT modified the 
distribution of fat and was a positive predictor of cIMT. Leptin- 
to-adiponectin ratio, a biomarker of abdominal obesity and 
the MS, and diastolic BP also determined cIMT, a marker of 
subclinical atherosclerosis. Nonetheless, adiposity-associated 
vascular disease might be attenuated by SAT. Changes in 
body fat must be evaluated in this group of patients in the 
early course of survivorship in order to avoid premature 
CVD associated with atherosclerosis. Yet, further research 
as regards the possible protective effect of SAT on vascular 
disease is warranted.
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